ALEXANDER'S INC. DL 1

Dr. Sandler brings more than 30 years of experience as a distinguished leader in oncology and drug development Dr. Sandler brings more than 30 years of experience as a distinguished leader in oncology and drug development» Mehr auf globenewswire.com

Alexander's, Inc. has underperformed since 2019, with a -1.7% TSR compared to SPY's 113%, due to declining profitability and rich valuations. Despite increasing NOPAT since 2020, the Company's GAAP net income and NOPAT margins have declined from 2019 highs, impacting overall profitability. Management has created value with $154 million in economic earnings since 2019, but ALX remains overvalued with unrealistic growth expectations.» Mehr auf seekingalpha.com

U.S. equity markets soared to record highs this week after President-elect Trump scored a surprisingly decisive election victory, including a likely "trifecta" of Republican legislative control in Congress. The outcome sparked powerful moves across global financial markets as investors priced in a combination of domestic-focused and "pro-growth" economic policies but also reflected concern over deficits and immigration policy. Characteristic of the "Trump trade" dynamic, smaller-cap companies led the surge, outperforming mega-cap technology and international-heavy peers. The S&P Small-Cap 600 soared 9%, outpacing 5% gains from the S&P 500.» Mehr auf seekingalpha.com